Advertisement

Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria

  • Lisandro D. ColantonioEmail author
  • Keri L. Monda
  • Robert S. Rosenson
  • Todd M. Brown
  • Katherine E. Mues
  • George Howard
  • Monika M. Safford
  • Larisa Yedigarova
  • Michael E. Farkouh
  • Paul Muntner
ORIGINAL ARTICLE

Abstract

Purpose

Determine the risk for cardiovascular disease (CVD) events among adults with clinically evident CVD who meet the inclusion criteria for the FOURIER clinical trial on PCSK9 inhibition in a real-world database.

Methods

We analyzed data from 2072 African American and 2972 white REasons for Geographic And Racial Differences in Stroke (REGARDS) study participants 45–85 years of age with clinically evident CVD. Study participants meeting the FOURIER inclusion criteria (one major or two minor cardiovascular risk factors, fasting LDL cholesterol ≥ 70 mg/dL or non-HDL cholesterol ≥ 100 mg/dL, triglycerides ≤ 400 mg/dL, and taking statin) were followed for CVD events (myocardial infarction, stroke, coronary revascularization, and CVD death) from baseline in 2003–2007 through 2014.

Results

Overall, 771 (37.2%) African Americans and 1200 (40.4%) whites met the FOURIER inclusion criteria. The CVD event rate per 1000 person years was 60.6 (95% CI 53.6–67.6) among African Americans and 63.5 (95% CI 57.7–69.3) among whites. The risk for CVD events among adults meeting the FOURIER inclusion criteria was higher for those with a history of multiple cardiovascular events (hazard ratios among African Americans and whites 1.34 [95% CI 1.05–1.71] and 1.34 [1.10–1.63], respectively), a prior coronary revascularization (1.44 [1.13–1.84] and 1.23 [1.00–1.52], respectively), diabetes (1.38 [1.08–1.76] and 1.41 [1.15–1.72], respectively), reduced glomerular filtration rate (1.63 [1.26–2.11] and 1.29 [1.03–1.62], respectively), and albuminuria (1.77 [1.37–2.27] and 1.33 [1.07–1.65], respectively).

Conclusions

The CVD event rate is high among African Americans and whites meeting the FOURIER inclusion criteria. Characteristics associated with a higher CVD risk may inform the decision to initiate PCSK9 inhibition.

Keywords

African Americans Cardiovascular diseases Mortality Continental population groups Epidemiology Evolocumab 

Notes

Acknowledgements

The authors thank the other investigators, the staff, and the participants of the REGARDS study for their valuable contributions. A full list of participating REGARDS investigators and institutions and further information about the study can be found at http://www.regardsstudy.org.

Funding

The design and conduct of the study, interpretation of the results, and preparation of the manuscript was supported through a research grant from Amgen, Inc. (Thousand Oaks, CA). The academic authors conducted all analyses and maintained the rights to publish this article. The REGARDS study is supported by a cooperative agreement U01 NS041588 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, Department of Health and Human Service. Representatives of the funding agency have been involved in the review of the manuscript but not directly involved in the collection, management, analysis, or interpretation of the data. Additional support was provided by grants R01 HL080477 and K24 HL111154 from the National Heart, Lung, and Blood Institute.

Compliance with Ethical Standards

Conflict of Interest

KLM, KEM, and LY are employed by Amgen, Inc. KLM and LY also are stockholders of Amgen, Inc. RSR, TMB, MMS, MEF, and PM receive research support from Amgen, Inc. RSR also receives research support from Akcea, Astra Zeneca, Medicines Company, Regeneron and Sanofi, serves on Advisory Boards for Akcea, Amgen, Inc., CVS Caremark, Easy Vitals, Regeneron and Sanofi, receives consulting fees and honoraria from Amgen, Regeneron, C5, CVS Caremark, Kowa and Pfizer, and receives royalties from UpToDate. TMB also receives research support from Astra Zeneca. PM also has received an honorarium from Amgen, Inc. LDC and GH have no disclosures.

Ethical Approval

All procedures performed in the current student were conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The REGARDS study protocol was approved by the Institutional Review Boards governing research in human subjects at the participating centers.

Informed Consent

Informed consent was obtained from all individual participants included in the REGARDS study.

Disclaimer

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.

Supplementary material

10557_2019_6864_MOESM1_ESM.docx (870 kb)
ESM 1 (DOCX 869 kb)

References

  1. 1.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.CrossRefGoogle Scholar
  2. 2.
    Kazi DS, Moran AE, Coxson PG, Penko J, Ollendorf DA, Pearson SD, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743–53.CrossRefGoogle Scholar
  3. 3.
    Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069–78.CrossRefGoogle Scholar
  4. 4.
    Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. JAMA Cardiol. 2017;2:1369–74.CrossRefGoogle Scholar
  5. 5.
    Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, et al. The REasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology. 2005;25:135–43.CrossRefGoogle Scholar
  6. 6.
    Carnethon MR, Pu J, Howard G, Albert MA, Anderson CAM, Bertoni AG, et al. Cardiovascular health in African Americans: a scientific statement from the American Heart Association. Circulation. 2017;136:e393–423.CrossRefGoogle Scholar
  7. 7.
    Gamboa CM, Colantonio LD, Brown TM, Carson AP, Safford MM. Race-sex differences in statin use and low-density lipoprotein cholesterol control among people with diabetes mellitus in the reasons for geographic and racial differences in stroke study. J Am Heart Assoc. 2017;6:e004264.CrossRefGoogle Scholar
  8. 8.
    Safford MM, Brown TM, Muntner PM, Durant RW, Glasser S, Halanych JH, et al. Association of race and sex with risk of incident acute coronary heart disease events. JAMA. 2012;308:1768–74.CrossRefGoogle Scholar
  9. 9.
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.Google Scholar
  10. 10.
    Levey AS, Stevens LA, Schmid CH, Zhang Y(L), Castro AF III, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–12.CrossRefGoogle Scholar
  11. 11.
    Sabatine MS, Giugliano RP, Keech A, Honarpour N, Wang H, Liu T, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016;173:94–101.CrossRefGoogle Scholar
  12. 12.
    Colantonio LD, Kent ST, Kilgore ML, Delzell E, Curtis JR, Howard G, et al. Agreement between Medicare pharmacy claims, self-report, and medication inventory for assessing lipid-lowering medication use. Pharmacoepidemiol Drug Saf. 2016;25:827–35.CrossRefGoogle Scholar
  13. 13.
    Xie F, Colantonio LD, Curtis JR, Safford MM, Levitan EB, Howard G, et al. Linkage of a population-based cohort with primary data collection to Medicare claims: the reasons for geographic and racial differences in stroke study. Am J Epidemiol. 2016;184:532–44.CrossRefGoogle Scholar
  14. 14.
    Howard VJ, Kleindorfer DO, Judd SE, McClure LA, Safford MM, Rhodes JD, et al. Disparities in stroke incidence contributing to disparities in stroke mortality. Ann Neurol. 2011;69:619–27.CrossRefGoogle Scholar
  15. 15.
    Soliman EZ, Howard G, Cushman M, Kissela B, Kleindorfer D, le A, et al. Prolongation of QTc and risk of stroke: the REGARDS (REasons for Geographic And Racial Differences in Stroke) study. J Am Coll Cardiol. 2012;59:1460–7.CrossRefGoogle Scholar
  16. 16.
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.CrossRefGoogle Scholar
  17. 17.
    Albright KC, Zhao H, Blackburn J, Limdi NA, Beasley TM, Howard G, et al. Racial differences in statin adherence following hospital discharge for ischemic stroke. Neurology. 2017;88:1839–48.CrossRefGoogle Scholar
  18. 18.
    Colantonio LD, Huang L, Monda KL, Bittner V, Serban MC, Taylor B, et al. Adherence to high-intensity statins following a myocardial infarction hospitalization among Medicare beneficiaries. JAMA Cardiol. 2017;2:890–5.CrossRefGoogle Scholar
  19. 19.
    Rosenson RS, Kent ST, Brown TM, Farkouh ME, Levitan EB, Yun H, et al. Underutilization of high-intensity statin therapy after hospitalization for coronary heart disease. J Am Coll Cardiol. 2015;65:270–7.CrossRefGoogle Scholar
  20. 20.
    Yun H, Safford MM, Brown TM, et al. Statin use following hospitalization among Medicare beneficiaries with a secondary discharge diagnosis of acute myocardial infarction. J Am Heart Assoc. 2015;4:e001208.CrossRefGoogle Scholar
  21. 21.
    Albright KC, Boehme AK, Tanner RM, Blackburn J, Howard G, Howard VJ, et al. Addressing stroke risk factors in black and white Americans: findings from the National Health and Nutrition Examination Survey, 2009-2010. Ethn Dis. 2016;26:9–16.CrossRefGoogle Scholar
  22. 22.
    Huxley RR, Bell EJ, Lutsey PL, Bushnell C, Shahar E, Rosamond W, et al. A comparative analysis of risk factors for stroke in blacks and whites: the atherosclerosis risk in communities study. Ethn Health. 2014;19:601–16.CrossRefGoogle Scholar
  23. 23.
    Carson AP, Howard G, Burke GL, Shea S, Levitan EB, Muntner P. Ethnic differences in hypertension incidence among middle-aged and older adults: the multi-ethnic study of atherosclerosis. Hypertension. 2011;57:1101–7.CrossRefGoogle Scholar
  24. 24.
    Nwankwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. NCHS Data Brief. 2013:1–8.Google Scholar
  25. 25.
    United States Renal Data System. Incidence, Prevalence, Patient Characteristics, and Treatment Modalities. 2015. In: USRDS annual data report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2015.Google Scholar
  26. 26.
    Yu SS, Castillo DC, Courville AB, Sumner AE. The triglyceride paradox in people of African descent. Metab Syndr Relat Disord. 2012;10:77–82.CrossRefGoogle Scholar
  27. 27.
    Colantonio LD, Gamboa CM, Richman JS, Levitan EB, Soliman EZ, Howard G, et al. Black-white differences in incident fatal, nonfatal, and total coronary heart disease. Circulation. 2017;136:152–66.CrossRefGoogle Scholar
  28. 28.
    Mathews R, Chen AY, Thomas L, et al. Differences in short-term versus long-term outcomes of older black versus white patients with myocardial infarction: findings from the can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of American College of Cardiology/American Heart Association Guidelines (CRUSADE). Circulation. 2014;130:659–67.CrossRefGoogle Scholar
  29. 29.
    Anstey DE, Li S, Thomas L, Wang TY, Wiviott SD. Race and sex differences in management and outcomes of patients after ST-elevation and non-ST-elevation myocardial infarct: results from the NCDR. Clin Cardiol. 2016;39:585–95.CrossRefGoogle Scholar
  30. 30.
    Patel N, Patel NJ, Macon CJ, Thakkar B, Desai M, Rengifo-Moreno P, et al. Trends and outcomes of coronary angiography and percutaneous coronary intervention after out-of-hospital cardiac arrest associated with ventricular fibrillation or pulseless ventricular tachycardia. JAMA Cardiol. 2016;1:890–9.CrossRefGoogle Scholar
  31. 31.
    Nallamothu BK, Lu X, Vaughan-Sarrazin MS, Cram P. Coronary revascularization at specialty cardiac hospitals and peer general hospitals in black Medicare beneficiaries. Circ Cardiovasc Qual Outcomes. 2008;1:116–22.CrossRefGoogle Scholar
  32. 32.
    Mark DB, Richman I, Hlatky MA. Proprotein convertase subtilisin/kexin type 9 inhibitor therapy-breakthrough in low-density lipoprotein cholesterol lowering, breakdown in value. JAMA Cardiol. 2017;2:1066–8.CrossRefGoogle Scholar
  33. 33.
    Centers for Medicare & Medicaid Services (CMS). Medicare program; Medicare prescription drug benefit. Final rule. Fed Regist. 2005;70:4193–585.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Lisandro D. Colantonio
    • 1
    Email author
  • Keri L. Monda
    • 2
  • Robert S. Rosenson
    • 3
  • Todd M. Brown
    • 4
  • Katherine E. Mues
    • 2
  • George Howard
    • 5
  • Monika M. Safford
    • 6
  • Larisa Yedigarova
    • 7
  • Michael E. Farkouh
    • 8
  • Paul Muntner
    • 1
  1. 1.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Center for Observational Research, Amgen Inc.Thousand OaksUSA
  3. 3.Mount Sinai HeartIcahn School of Medicine at Mount SinaiNew YorkUSA
  4. 4.Department of MedicineUniversity of Alabama at BirminghamBirminghamUSA
  5. 5.Department of BiostatisticsUniversity of Alabama at BirminghamBirminghamUSA
  6. 6.Department of MedicineWeill Cornell Medical CollegeNew YorkUSA
  7. 7.Amgen Inc.Thousand OaksUSA
  8. 8.Peter Munk Cardiac CentreUniversity of Toronto and Heart and Stroke Richard Lewar Centre of ExcellenceTorontoCanada

Personalised recommendations